Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | FG-3246 |
Synonyms | |
Therapy Description |
Limited information is currently available on FG-3246, a putative antibody-drug conjugate (ADC) targeting CD46 (Mar 2025). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
FG-3246 | FG 3246|FG3246 | Limited information is currently available on FG-3246, a putative antibody-drug conjugate (ADC) targeting CD46 (Mar 2025). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06842498 | Phase II | FG-3246 | A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Not yet recruiting | USA | 0 |